At Immunocodex, we are committed to finding novel breakthroughs for the treatment of autoimmune diseases. We are pioneering the development of innovative lipid nanoparticle mRNA-based therapies designed to induce antigen-specific immune tolerance. Unlike conventional treatments that broadly suppress the immune system and may lead to severe side effects, our strategy aims to induce specificity and precision. Immunocodex's proprietary drug development method specifically targets dendritic cells – the cells responsible for coordinating immune system responses, and delivers an active tolerogenic signal that re-programs these cells and promotes an anti-inflammatory phenotype. This approach offers a unique and targeted means to effectively manage autoimmune diseases while minimizing potential adverse effects.

 

Immunocodex is guided by a team of experienced and knowledgeable scientists, advisors, board members, and collaborators committed to the advancement of immunotherapy and the development of innovative therapeutics. Immunocodex was founded based on pioneering research conducted in the field of immune tolerance by the company's scientific founder, Dr. Francisco J. Quintana, at Brigham and Women’s Hospital and Harvard Medical School.

​

Meet Our Team

 

​